Zhu S - Search Results

1

Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer.

Zhang H, Zhu S, Zhou H, Li R, Xia X, Xiong H. Zhang H, et al. Among authors: zhu s. Front Oncol. 2023 Jan 16;13:1098357. doi: 10.3389/fonc.2023.1098357. eCollection 2023. Front Oncol. 2023. PMID: 36726381 Free PMC article.

2

The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.

Zhang H, Zhu S, Deng W, Li R, Zhou H, Xiong H. Zhang H, et al. Among authors: zhu s. Front Immunol. 2022 Jul 22;13:887471. doi: 10.3389/fimmu.2022.887471. eCollection 2022. Front Immunol. 2022. PMID: 35935930 Free PMC article. Review.

3

Retinal determination gene networks: from biological functions to therapeutic strategies.

Zhu S, Li W, Zhang H, Yan Y, Mei Q, Wu K. Zhu S, et al. Biomark Res. 2023 Feb 8;11(1):18. doi: 10.1186/s40364-023-00459-8. Biomark Res. 2023. PMID: 36750914 Free PMC article. Review.

4

Recent advances in targeted strategies for triple-negative breast cancer.

Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, Wu K. Zhu S, et al. J Hematol Oncol. 2023 Aug 28;16(1):100. doi: 10.1186/s13045-023-01497-3. J Hematol Oncol. 2023. PMID: 37641116 Free PMC article. Review.

5

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.

Yi M, Niu M, Zhang J, Li S, Zhu S, Yan Y, Li N, Zhou P, Chu Q, Wu K. Yi M, et al. Among authors: zhu s. J Hematol Oncol. 2021 Sep 15;14(1):146. doi: 10.1186/s13045-021-01155-6. J Hematol Oncol. 2021. PMID: 34526097 Free PMC article.

6

Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies.

Zhu S, Yi M, Wu Y, Dong B, Wu K. Zhu S, et al. Exp Hematol Oncol. 2021 Dec 29;10(1):60. doi: 10.1186/s40164-021-00252-z. Exp Hematol Oncol. 2021. PMID: 34965886 Free PMC article. Review.

7

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.

Yi M, Niu M, Wu Y, Ge H, Jiao D, Zhu S, Zhang J, Yan Y, Zhou P, Chu Q, Wu K. Yi M, et al. Among authors: zhu s. J Hematol Oncol. 2022 Oct 8;15(1):142. doi: 10.1186/s13045-022-01363-8. J Hematol Oncol. 2022. PMID: 36209176 Free PMC article.

8

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.

Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, Zhou P, Dai Z, Wu K. Yi M, et al. Among authors: zhu s. J Immunother Cancer. 2022 Dec;10(12):e005543. doi: 10.1136/jitc-2022-005543. J Immunother Cancer. 2022. PMID: 36460337 Free PMC article.

9

Focal adhesion kinase: from biological functions to therapeutic strategies.

Tan X, Yan Y, Song B, Zhu S, Mei Q, Wu K. Tan X, et al. Among authors: zhu s. Exp Hematol Oncol. 2023 Sep 25;12(1):83. doi: 10.1186/s40164-023-00446-7. Exp Hematol Oncol. 2023. PMID: 37749625 Free PMC article. Review.

10

MiRNA-mediated EMT and CSCs in cancer chemoresistance.

Dong B, Li S, Zhu S, Yi M, Luo S, Wu K. Dong B, et al. Among authors: zhu s. Exp Hematol Oncol. 2021 Feb 12;10(1):12. doi: 10.1186/s40164-021-00206-5. Exp Hematol Oncol. 2021. PMID: 33579377 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17,402 results

Search Page

Filters